Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Dynorphin

    go.drugbank.com/drugs/DB16146
    Investigational

    Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).

  2. Drug

    C-peptide

    go.drugbank.com/drugs/DB16187
    Investigational

    C-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).

  3. Drug

    Evobrutinib

    go.drugbank.com/drugs/DB15170
    Investigational

    Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).

  4. Drug

    Rilmenidine

    go.drugbank.com/drugs/DB11738
    ApprovedWithdrawn

    Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.

    Products: Iterium 1 mg - Tabletten, HYPERIUM 1 MG TABLET, 30 ADET
  5. Drug

    Isoxaflutole

    go.drugbank.com/drugs/DB12938
    ApprovedWithdrawn

    Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.

  6. Drug

    Dichlorotetrafluoroethane

    go.drugbank.com/drugs/DB20118
    ApprovedWithdrawn

    Dichlorotetrafluoroethane has a monoisotopic molecular weight of 169.93 Da.

  7. Drug

    Iopydone

    go.drugbank.com/drugs/DB20831
    ApprovedWithdrawn

    Iopydone has a monoisotopic molecular weight of 346.83 Da.

  8. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia). … Canosimibe has a monoisotopic molecular weight of 809.43 Da.

  9. Drug

    Bradanicline

    go.drugbank.com/drugs/DB06090
    Investigational

    Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).

  10. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    It is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.